{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:20:23Z","timestamp":1791249623708,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.purol.2012.04.019","type":"journal-article","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T00:26:58Z","timestamp":1343435218000},"page":"989-998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Diagnostic et prise en charge des \u00e9v\u00e9nements ind\u00e9sirables survenant au d\u00e9cours des instillations endov\u00e9sicales de BCG pour le traitement des tumeurs de vessie n\u2019infiltrant pas le muscle (TVNIM)\u00a0: revue du comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie"],"prefix":"10.1016","volume":"22","author":[{"given":"Y.","family":"Neuzillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wallerand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Larr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Davin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Souli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2012.04.019_bib0005","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0010","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S1166-7087(10)70043-9","article-title":"Recommandations en onco-urologie 2010\u00a0: tumeurs uroth\u00e9liales","volume":"20","author":"Pfister","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long- term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.purol.2009.06.009","article-title":"Traitement par instillations v\u00e9sicales de BCG et mitomycine C dans les tumeurs de vessie n\u2019infiltrant pas le muscle\u00a0: enqu\u00eate de pratique de l\u2019Afu aupr\u00e8s des urologues fran\u00e7ais","volume":"19","author":"Descazeaud","year":"2009","journal-title":"Prog Urol."},{"key":"10.1016\/j.purol.2012.04.019_bib0025","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1166-7087(10)70025-7","article-title":"Traitements des cancers de vessie\u00a0: les vraies contre-indications du BCG","volume":"20","author":"Neuzillet","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0030","first-page":"1175","article-title":"Enqu\u00eate sur les tumeurs superficielle de la vessie aupr\u00e8s des membres de l\u2019Association fran\u00e7aise d\u2019urologie","volume":"11","author":"Gattegno","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0035","first-page":"1067","article-title":"Immunoth\u00e9rapie endov\u00e9sicale\u00a0: le bacille de Calmette et Gu\u00e9rin","volume":"11","author":"Chopin","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/imt.10.32","article-title":"Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer","volume":"2","author":"Alexandroff","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.purol.2012.04.019_bib0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-1-4615-4737-2_25","article-title":"Pathophysiology of bacterial cystitis","volume":"462","author":"Roberts","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.purol.2012.04.019_bib0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","article-title":"Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy","volume":"99","author":"Jackson","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.purol.2012.04.019_bib0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/jaut.2000.0494","article-title":"BCG and autoimmunity: another two-edged sword","volume":"16","author":"Shoenfeld","year":"2001","journal-title":"J Autoimmun"},{"key":"10.1016\/j.purol.2012.04.019_bib0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaut.2005.01.005","article-title":"Infection-induced apoptosis deletes bystander CD4+ T cells: a mechanism for suppression of autoimmunity during BCG infection","volume":"24","author":"O\u2019Connor","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.purol.2012.04.019_bib0065","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gut.38.4.616","article-title":"Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation","volume":"38","author":"Leebeek","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.purol.2012.04.019_bib0070","first-page":"169","article-title":"Est-il possible d\u2019\u00e9valuer la sous-notification des effets ind\u00e9sirable m\u00e9dicamenteux par la m\u00e9thode capture\/recapture\u00a0?","volume":"51","author":"Jonville-bera","year":"1996","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.purol.2012.04.019_bib0075","first-page":"335","article-title":"Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602\u00a0patients and comparison of chemotherapy complications","volume":"310","author":"Lamm","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.purol.2012.04.019_bib0080","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1\u00a0and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complication of Bacillus Calmette-Gu\u00e9rin intravesical th\u00e9rapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0090","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Gu\u00e9rin in patients with superficial bladder carcinoma","volume":"156","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0095","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0022-5347(05)67025-5","article-title":"Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin","volume":"164","author":"Leibovici","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0100","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","article-title":"Complications of intravesical therapy for urothelial cancer of the bladder","volume":"175","author":"Koya","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.purol.2012.04.019_bib0110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01302-08","article-title":"Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics","volume":"53","author":"Ritz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.purol.2012.04.019_bib0115","first-page":"5671","article-title":"Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections","volume":"18","author":"Malhotra","year":"2011","journal-title":"Can J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/cid\/ciq002","article-title":"Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin used for immunotherapy in bladder cancer","volume":"52","author":"Watts","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.purol.2012.04.019_bib0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.purol.2012.04.019_bib0130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10067-004-1063-8","article-title":"Reactive arthritis following BCG immunotherapy for bladder carcinoma","volume":"24","author":"Tinazzi","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.purol.2012.04.019_bib0135","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00042737-200410000-00012","article-title":"Bacillus Calmette-Gu\u00e9rin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma","volume":"16","author":"Van Outryve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.purol.2012.04.019_bib0140","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacine on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy \u2013 associated adverse events","volume":"S7","author":"Witjes","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0150","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Gu\u00e8rin therapy: experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"Andius","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2012.04.019_bib0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1\u00a0bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.04.019_bib0165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2004.07.027","article-title":"Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Gu\u00e9rin therapy for superficial bladder carcinoma","volume":"65","author":"Falkensammer","year":"2005","journal-title":"Urology"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708712001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708712001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:22:29Z","timestamp":1761114149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708712001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1166708712001911"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2012.04.019","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic et prise en charge des \u00e9v\u00e9nements ind\u00e9sirables survenant au d\u00e9cours des instillations endov\u00e9sicales de BCG pour le traitement des tumeurs de vessie n\u2019infiltrant pas le muscle (TVNIM)\u00a0: revue du comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2012.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}